10-Q: Vystar Reports Q3 Loss Amid Revenue Decline, Going Concern Doubts

Vystar Corporation reported a net loss of $271,387 for Q3 2025, with revenues down 61.6% year-over-year, and disclosed substantial doubt about its ability to continue as a going concern.

Summary

• Net loss attributable to Vystar for the three months ended September 30, 2025, was $271,387, an improvement from $347,751 in the prior year period.
• Net loss attributable to Vystar for the nine months ended September 30, 2025, worsened to $1,236,401, compared to $997,449 for the same period in 2024.
• Revenue for the three months ended September 30, 2025, decreased by 61.6% to $20,385 from $53,094 in the prior year, partly due to a bulk sale of Vytex in 2024.
• Revenue for the nine months ended September 30, 2025, decreased by 65.3% to $44,657 from $128,770 in the prior year, attributed to reduced sales to a former major customer and a special bulk sale of Vytex in 2024.
• Gross profit for the three months ended September 30, 2025, was $15,365, a 57.3% decrease, and for the nine months, it was $26,054, a 63.5% decrease, both due to decreased sales and increased channel costs.
• Operating expenses decreased by 10.7% for the three-month period and 4.1% for the nine-month period, primarily due to the temporary suspension of consulting fees to Blue Oar and a decrease in professional fees, partially offset by an increase in share-based compensation.
• Interest expense decreased significantly for the three-month period but increased by 119.5% for the nine-month period to $303,943, largely due to accrued interest and amortization of debt discount on related party debt.
• The company reported a loss on settlement of debt, net, of $79,846 for the nine months ended September 30, 2025, related to the conversion of shareholder convertible notes.
• Cash on hand at September 30, 2025, was $16,584, an increase from $7,712 at December 31, 2024.
• The company had a working capital deficit of approximately $6.3 million and an accumulated deficit of approximately $61.1 million at September 30, 2025.
• Net cash used in operating activities increased to $166,263 for the nine months ended September 30, 2025, from $79,902 in the prior year period.
• Net cash provided by financing activities increased to $174,679 for the nine months ended September 30, 2025, from $61,986 in the prior year period, driven by advances from stock subscription payable and common stock issuances.
• The EMA Financial lawsuit was resolved in Vystar's favor by the Second Circuit Court of Appeals on July 17, 2025, with the case returning to the District Court for a determination of legal fees to be awarded to Vystar.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including significant losses, negative working capital, and substantial doubt about its ability to continue as a going concern. Revenue has declined sharply, and while some operating expenses were managed, overall losses for the nine-month period worsened. The reliance on equity financing and potential M&A for survival, coupled with identified material weaknesses in internal controls, indicates a highly precarious situation, despite a favorable legal outcome.

Positives

• Net loss for the three months ended September 30, 2025, improved by 22.0% compared to the same period in 2024.
• Cash on hand increased to $16,584 at September 30, 2025, from $7,712 at December 31, 2024.
• Operating expenses decreased by 10.7% for the three-month period and 4.1% for the nine-month period, partly due to cost-saving measures like the temporary suspension of consulting fees.
• The EMA Financial lawsuit, which sought significant damages against the company, was definitively resolved in Vystar's favor by the Second Circuit Court of Appeals, with Vystar now awaiting a determination of legal fees to be awarded.
• Discontinued operations (Rotmans) showed a significant reduction in loss, indicating the successful winding down of that segment.

Negatives

• Net loss for the nine months ended September 30, 2025, worsened by 24.0% compared to the same period in 2024.
• Revenue for both the three and nine months ended September 30, 2025, decreased significantly by 61.6% and 65.3% respectively, indicating a substantial decline in sales.
• Gross profit declined by 57.3% for the three-month period and 63.5% for the nine-month period, reflecting lower sales and increased channel costs.
• Interest expense for the nine months ended September 30, 2025, increased by 119.5%, significantly impacting profitability.
• The company recorded a loss on settlement of debt of $79,846 for the nine months ended September 30, 2025.
• Net cash used in operating activities increased, indicating a higher cash burn rate.
• The company continues to operate with a significant working capital deficit of approximately $6.3 million and an accumulated deficit of approximately $61.1 million.
• Management has identified material weaknesses in internal control over financial reporting, including a lack of segregation of duties, inadequate control over transaction records, and the absence of a functioning audit committee.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to significant losses and negative cash flow since inception, and a working capital deficit of approximately $6.3 million.
• The company's future success is dependent on obtaining sufficient financing and achieving adequate revenue levels, with no assurances that projected revenue will be met or additional financing secured.
• Failure to achieve projected revenue and obtain additional financing could lead to significant curtailment or reorientation of operations, potential bankruptcy, or cessation of operations.
• Future production of RxAir products and FEC devices may be impacted by fluctuations in tariffs by the U.S. government and cash flow constraints.
• The company is exposed to risks pertinent to a retailer's operations, including the ability to acquire new customers, maintain a strong brand, and broader economic factors like interest rates and changes in customer spending patterns.
• Material weaknesses in internal control over financial reporting, including lack of segregation of duties and a functioning audit committee, could lead to material misstatements in financial statements.

Future Outlook

Management plans to finance future operations using cash on hand, increased revenue from RxAir air purification units and Vytex license fees, and stock issuances to new and existing shareholders. The company is exploring merger and acquisition opportunities, including a reverse merger of its RxAir division and a second spinout, sale, or other transaction involving the Vytex and FEC divisions. There are no assurances that projected revenue levels will be achieved in 2025 and beyond, or that alternate additional financing will be obtained. Production of new RxAir and FEC devices is delayed to 2026-2027 due to tariffs and cash flow, with a smaller RxAir unit for automobiles and refrigerators expected to be designed in 2026.

Management Comments

• Management plans to finance future operations using cash on hand, increased revenue from RxAir air purification units, Vytex license fees and stock issuances to new and existing shareholders.
• The company will continue to review its pricing and sales strategies in the fourth quarter of 2025 and into 2026.
• Management expects to strengthen internal control during 2025 by developing stronger business and financial processes for accounting for transactions, which will enhance internal control for the Company.

Industry Context

The company operates in the air purification, natural rubber latex, and fluid energy conversion sectors. The decline in revenue for Vytex was partly due to a bulk sale in the prior year, suggesting inconsistent demand or sales strategy. The focus on new RxAir prototypes and exploring new applications for Vytex (green tires, bioelastoplasts) indicates an effort to innovate and diversify within its existing markets. The mention of tariffs impacting future production highlights broader geopolitical and economic challenges affecting manufacturing and supply chains, particularly for companies with international operations or sourcing. The exploration of tokenizing real-world collectibles through GOPAID.COM, LLC suggests a potential diversification into emerging digital asset markets, which is a significant departure from its core businesses and could be a response to the challenges in its traditional segments.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The EMA Financial lawsuit, alleging breaches of a convertible promissory note and stock purchase agreement, was resolved in Vystar's favor by the Second Circuit Court of Appeals on July 17, 2025. The case has been remanded to the District Court for a determination of legal fees to be awarded to Vystar. As of November 12, 2025, the company is awaiting this decision.

Related Party Transactions

• Jamie Rotman (President, CEO, CFO, Director, daughter of former CEO Steven Rotman) has an employment agreement with annual compensation of $180,000 (payable in preferred or common stock at a 50% discount, or cash at her discretion) and a $25,000 signing bonus. The company expensed approximately $305,000 for this agreement in the nine months ended September 30, 2025. She also has a stock subscription payable balance of $668,920 for approximately 26.8 million shares.
• Blue Oar Consulting, Inc. (owned by Gregory Rotman, brother of Jamie Rotman) provides business consulting services. The company expensed approximately $254,000 for these services in the nine months ended September 30, 2025. Blue Oar received 1,900,735 shares of common stock for past services and has a stock subscription payable balance of $1,043,044 for approximately 110.5 million shares. A term convertible promissory note with Blue Oar allows for borrowing up to $1,000,000 at 12% interest, with payments potentially in common stock at a 50% discount, and resulted in a derivative liability of $356,142.
• Dr. Bryan Stone (Director) receives a $25 per unit commission for RxAir units sold to a specific customer. Commissions of $124 were due to him at September 30, 2025.
• Steven Rotman (Former Officer and Director) has a stock subscription payable balance of $427,933 for approximately 59.2 million shares, $243,155 in reimbursable expenses payable, and $81,482 in unpaid salary. He is also owed $77,460 from Vystar and $61,986 from Rotmans in advances due on demand.

Stakeholder Impact

• Shareholders face significant dilution risk due to ongoing stock issuances for financing, debt conversions, and compensation, as evidenced by the increase in common shares outstanding and substantial stock subscription payable balances.
• Creditors, particularly related parties, are exposed to the company's precarious financial health and going concern doubts, although some related party debt has conversion features or extended maturities.
• Employees and management, including Jamie Rotman, are receiving compensation partly in stock, aligning their interests with share performance but also exposing them to the company's financial risks.
• Customers may experience delays in new product introductions (e.g., RxAir prototype, FEC devices) due to production delays caused by tariffs and cash flow issues.
• The company's ability to attract and retain talent may be impacted by its financial instability and material weaknesses in internal controls.

Next Steps

• Review pricing and sales strategies in the fourth quarter of 2025 and into 2026.
• Strengthen internal control over financial reporting during 2025 by developing stronger business and financial processes.
• Run a trial on FEC/Hughes devices for hard water abatement and dialysis membrane efficiency by the end of the year.
• Explore production options for the RX600 (formerly RX300) air purifier prototype.
• Design a smaller RxAir unit for automobiles and refrigerators with USB charging during 2026.
• Proceed with production of the RxAir prototype integrating Fluid Energy conversion technology in 2026-2027.
• Continue to monitor current developments in trade policy and tariff actions by the U.S. government.
• Continue exploring a reverse merger or other transaction of the RxAir division.
• Continue exploring a second spinout, sale, or other transaction involving the Vytex and FEC divisions.
• Continue discussions to acquire a minority interest in GOPAID.COM, LLC.
• Await the District Court's decision on legal fees to be awarded to Vystar in the EMA Financial lawsuit.

Key Dates

Recommendation

Vystar Corporation presents an extremely high-risk investment profile. The company has a history of significant losses, negative cash flow, and a substantial working capital deficit, leading to explicit 'going concern' doubts. Revenue has plummeted by over 60% year-over-year, and while some operating expenses were cut, the nine-month net loss worsened significantly. The reliance on continuous stock issuances for financing indicates severe liquidity issues and will lead to further substantial dilution for existing shareholders. Identified material weaknesses in internal controls and the absence of a functioning audit committee raise serious governance concerns. Despite a favorable legal outcome, the fundamental financial health is deteriorating rapidly, making the stock highly speculative with a strong likelihood of further value erosion.

Keywords

Vystar Corporation, 10-Q, Quarterly Report, Financial Results, Net Loss, Revenue Decline, Going Concern, RxAir, Air Purifiers, Vytex, Natural Rubber Latex, Fluid Energy Conversion, FEC, Hughes Reactor, SEC Filing, Financial Health, Corporate Governance, Legal Proceedings, Capital Raise, Stock Subscription, Related Party Transactions